A Phase 2, Open-label, Single-arm Rollover Study to Evaluate Long-term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Solid Tumors and Hematological Disorders.

Trial Profile

A Phase 2, Open-label, Single-arm Rollover Study to Evaluate Long-term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Solid Tumors and Hematological Disorders.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 14 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top